Bagnols-sur-Cèze, France
Bagnols-sur-Cèze, France

Time filter

Source Type

Comps-Agrar L.,French National Center for Scientific Research | Comps-Agrar L.,French Institute of Health and Medical Research | Comps-Agrar L.,Universites Of Montpellier 1 And 2 | Kniazeff J.,French National Center for Scientific Research | And 23 more authors.
EMBO Journal | Year: 2011

G protein-coupled receptors (GPCRs) have key roles in cell-cell communication. Recent data suggest that these receptors can form large complexes, a possibility expected to expand the complexity of this regulatory system. Among the brain GPCRs, the heterodimeric GABA B receptor is one of the most abundant, being distributed in most brain regions, on either pre- or post-synaptic elements. Here, using specific antibodies labelled with time-resolved FRET compatible fluorophores, we provide evidence that the heterodimeric GABA B receptor can form higher-ordered oligomers in the brain, as suggested by the close proximity of the GABA B1 subunits. Destabilizing the oligomers using a competitor or a GABA B1 mutant revealed different G protein coupling efficiencies depending on the oligomeric state of the receptor. By examining, in heterologous system, the G protein coupling properties of such GABA B receptor oligomers composed of a wild-type and a non-functional mutant heterodimer, we provide evidence for a negative functional cooperativity between the GABA B heterodimers. © 2011 European Molecular Biology Organization | All Rights Reserved.


News Article | November 21, 2016
Site: www.prnewswire.co.uk

The worldwide immunoassay market to 2021 is propelled by extensive use of immunoassays in oncology, technological advancements and cost-effectiveness & rapid analysis of immunoassays while reagents & kits segment is expected to dominate globally with more than 8% CAGR to hit USD 25.45 billion by 2021 Complete report on immunoassay market spread across 185 pages, profiling 10 companies and supported with 139 tables and 44 figures is now available at http://www.reportsnreports.com/reports/269708-immunoassay-market-technology-enzyme-fluorescent-chemiluminescence-radioimmunoassay-analyzers-reagents-applications-infectious-diseases-cancer-endocrinology-cardiology-end-users-hospitals-laboratory-academics-global-forecast-to-2018.html . The immunoassay market is expected to reach USD 25.45 billion by 2021 from USD 17.16 billion in 2016 at a CAGR of 8.2%. The global immunoassay market is segmented based on product & service, technology, application, end user, and region. The reagents & kits segment is expected to account for the largest market share of the immunoassay market during the forecast period. The high growth in this segment can be attributed to the expanding use of immunoassay tests worldwide. On the basis of technology, the ELISA segment is expected to account for the largest share of the market in 2016. Expanding use of immunoassay tests in cancer, point-of-care in vitro diagnostics, infectious disease testing, and therapeutic drug level monitoring as well as the introduction of novel biomarkers will drive the growth of this market. On the basis of application, the market is segmented into infectious diseases, endocrinology, bone and mineral disorders, oncology, cardiology, hematology and blood screening, autoimmune diseases, toxicology, neonatal screening, and other applications. The rise in incidence of HIV, tuberculosis, hepatitis, and other hospital-acquired infections has fueled the demand for immunoassay tests in the infectious diseases segment. Geographically, the immunoassay market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American region is primarily driven by rapidly increasing aging population and the concomitant rise in the prevalence of diseases as well as the growing life expectancy. The major players in this market include F. Hoffmann-La Roche Ltd. (Switzerland), Siemens AG (Germany), Abbott Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Ortho-Clinical Diagnostics, Inc. (U.S.), and bioMérieux SA (France). Order a copy of Immunoassay Market by Product & Service (Reagents & Kits, Analyzers, Software, Services), Technique (ELISA, Rapid Test), Application (Infectious Diseases, Endocrinology, Oncology), End User (Clinical Labs, Hospitals) - Global Forecast to 2021 research report at http://www.reportsnreports.com/purchase.aspx?name=269708 . The major factors contributing to the growth of the immunoassay market include rising incidences of chronic diseases, extensive use of immunoassays in oncology, technological advancements, cost-effectiveness & rapid analysis of immunoassays. On a related note, another research on Radioimmunoassay Market Global Forecast to 2020 says, the global radioimmunoassay (RIA) market constituted 2.3% share of the global immunoassay market. The global market is expected to reach $428.4 million by 2020, at a CAGR of 3.5% during the forecast period from 2015 to 2020. Oncology testing is the largest application segment and is expected to hold the largest market share. Companies like DIAsource ImmunoAssays SA, Beckman Coulter, Inc., IBL International, PerkinElmer, Inc., DRG International, Inc., MP Biomedicals, LLC, Cisbio, Euro Diagnostica AB, DiaSorin S.p.A., EMD Millipore, Izotop, Berthold Technologies GmbH & Co. KG and  Stratec Biomedical AG have been profiled in this 113 pages research report available at http://www.reportsnreports.com/reports/430222-radioimmunoassay-market-by-type-reagents-kits-analyzers-end-user-hospital-pharmaceutical-industry-academics-clinical-diagnostic-labs-application-research-clinical-diagnostics-and-geography-global-forecast-to-2020.html . Explore more reports on the medical devices market at http://www.reportsnreports.com/market-research/medical-devices/ . ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on:


News Article | November 30, 2016
Site: www.newsmaker.com.au

Increasing use of radioimmunoassay (RIA) in in-vitro diagnostics segment of the healthcare industry such as research institutes, diagnostic laboratories, pharmaceutical companies, and other healthcare settings, has led to increase in demand for radioimmunoassay kits. Widened applications of the radioimmunoassay technique such as radioimmunoassay for measuring progesterone in cow’s milk is expected to fuel the demand for radioimmunoassay kits. Furthermore, technological advances in the field of in-vitro diagnostics, increasing demand for accuracy and quality results, and demand for more advanced reagents and kits, is expected to drive the growth of the global radioimmunoassay kits market during the forecast period of 2016-2024. But, use of hazardous radioactive materials in the assay, and high cost of equipment required for the procedure, are some factors which are anticipated to limit the growth of the global radioimmunoassay kits market. Based on applications, the oncology testing application accounted for the largest market share of the global radioimmunoassay kits market in 2015. Increasing tobacco smoking and other carcinogenic factors has led to an increase in number of cancer patients and it has been the major factor driving the growth of the oncology application segment in the global radioimmunoassay kits market. According to the American Cancer Society, in 2015, there were around 15.4 Mn cancer survivors in the U.S. alone, with almost 1.6 Mn new cancer cases detected every year. Prostate cancer was the most prevalent forms of cancer in males with around 3.3 Mn people suffering from it in 2015, while in females, breast cancer was the most prevalent affecting an estimated 3.5 Mn females in the U.S. in 2015. Also, a booming allergy testing segment due to increasing prevalence of food and inhaled allergies around the world, is expected to drive the segment growth in the global radioimmunoassay kits market during the forecast period of 2016-2024. On the basis of regional presence, global radioimmunoassay kits market is segmented into five key regions viz.  North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America region is expected to lead the global radioimmunoassay kits market due to advanced healthcare infrastructure, advancements in diagnostic technologies, higher demand for quality and accurate tests, and availability of reimbursement policies. Asia Pacific market is anticipated to grow at the fastest growth rate during the forecast period, owing to factors such as increasing cancer incidences and allergies especially food allergies in countries of China, Japan, Singapore, Australia and India. Growing medical tourism and high growth of the In-vitro Diagnostics (IVD) in these countries, is expected to drive the growth of radioimmunoassay kits market during the forecast period of 2016-2024. Request TOC (desk of content material), Figures and Tables of the report: http://www.persistencemarketresearch.com/toc/12298 Some of the major players in global radioimmunoassay kits market are Beckman Coulter, DIAsource ImmunoAssays SA, DiaSorin S.p.A., EMD Millipore (U.S.), Berthold Technologies GmbH & Co. KG, Cisbio, IBL International, Euro Diagnostica AB, Izotop, MP Biomedicals, PerkinElmer, Stratec Biomedical AG, DRG International.


News Article | November 24, 2016
Site: www.newsmaker.com.au

Radioimmunoassay (RIA), is an in-vitro technique, used for measuring concentrations of various antigens such as hormones, which are of clinical and biological importance. Radioimmunoassay works on the principle of binding assay, in which the binder is an antibody, which binds to the antigen, and the amount of bound antigen is measured using radioactivity. Radioimmunoassay has gained significant importance in the field of medical diagnostics, due to certain factors such as precision, accuracy, specificity of results, and sensitivity. Radioimmunoassay involves three important factors, a pure antigen, a radio labelled antigen, and an antibody, along with a separation unit to evaluate the distribution of radioactivity in free and bound antigens. The accuracy and sensitivity of the assay mainly depends upon the quality of antigens and antibodies taken, and the choice of separation techniques. Radioimmunoassay kits are used to perform the in-vitro procedure of the assay. The kits come in varied forms and types, and include a buffer solution for radioimmunoassay, a standard peptide in lyophilized powder form, an antibody in lyophilized powder which is specific to the antigen / peptide, a normal IgG serum, and an antibody IgG serum, along with a positive control for the test, and a separation technique of choice. The radioimmunoassay kits include, plates, tubes and reagents for different number of tests such as 50 test, 100 tests, 125 tests, etc. Increasing use of radioimmunoassay (RIA) in in-vitro diagnostics segment of the healthcare industry such as research institutes, diagnostic laboratories, pharmaceutical companies, and other healthcare settings, has led to increase in demand for radioimmunoassay kits. Widened applications of the radioimmunoassay technique such as radioimmunoassay for measuring progesterone in cow’s milk is expected to fuel the demand for radioimmunoassay kits. Furthermore, technological advances in the field of in-vitro diagnostics, increasing demand for accuracy and quality results, and demand for more advanced reagents and kits, is expected to drive the growth of the global radioimmunoassay kits market during the forecast period of 2016-2024. But, use of hazardous radioactive materials in the assay, and high cost of equipment required for the procedure, are some factors which are anticipated to limit the growth of the global radioimmunoassay kits market. Request TOC (desk of content material), Figures and Tables of the report: http://www.persistencemarketresearch.com/toc/12298? Based on applications, the oncology testing application accounted for the largest market share of the global radioimmunoassay kits market in 2015. Increasing tobacco smoking and other carcinogenic factors has led to an increase in number of cancer patients and it has been the major factor driving the growth of the oncology application segment in the global radioimmunoassay kits market. According to the American Cancer Society, in 2015, there were around 15.4 Mn cancer survivors in the U.S. alone, with almost 1.6 Mn new cancer cases detected every year. Prostate cancer was the most prevalent forms of cancer in males with around 3.3 Mn people suffering from it in 2015, while in females, breast cancer was the most prevalent affecting an estimated 3.5 Mn females in the U.S. in 2015. Also, a booming allergy testing segment due to increasing prevalence of food and inhaled allergies around the world, is expected to drive the segment growth in the global radioimmunoassay kits market during the forecast period of 2016-2024. On the basis of regional presence, global radioimmunoassay kits market is segmented into five key regions viz.  North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America region is expected to lead the global radioimmunoassay kits market due to advanced healthcare infrastructure, advancements in diagnostic technologies, higher demand for quality and accurate tests, and availability of reimbursement policies. Asia Pacific market is anticipated to grow at the fastest growth rate during the forecast period, owing to factors such as increasing cancer incidences and allergies especially food allergies in countries of China, Japan, Singapore, Australia and India. Growing medical tourism and high growth of the In-vitro Diagnostics (IVD) in these countries, is expected to drive the growth of radioimmunoassay kits market during the forecast period of 2016-2024. Some of the major players in global radioimmunoassay kits market are Beckman Coulter, DIAsource ImmunoAssays SA, DiaSorin S.p.A., EMD Millipore (U.S.), Berthold Technologies GmbH & Co. KG, Cisbio, IBL International, Euro Diagnostica AB, Izotop, MP Biomedicals, PerkinElmer, Stratec Biomedical AG, DRG International.


Gaborit N.,Institut Universitaire de France | Larbouret C.,Institut Universitaire de France | Vallaghe J.,Cisbio | Peyrusson F.,Cisbio | And 8 more authors.
Journal of Biological Chemistry | Year: 2011

In oncology, simultaneous inhibition of epidermal growth factor receptor (EGFR) and HER2 by monoclonal antibodies (mAbs) is an efficient therapeutic strategy but the underlying mechanisms are not fully understood. Here, we describe a time-resolved fluorescence resonance energy transfer (TR-FRET) method to quantify EGFR/HER2 heterodimers on cell surface to shed some light on the mechanism of such therapies. First, we tested this antibody-based TR-FRET assay in NIH/3T3 cell lines that express EGFR and/or HER2 and in various tumor cell lines. Then, we used the antibody-based TR-FRET assay to evaluate in vitro the effect of different targeted therapies on EGFR/HER2 heterodimers in the ovarian carcinoma cell line SKOV-3. A simultaneous incubation with Cetuximab (anti-EGFR) and Trastuzumab (anti-HER2) disturbed EGFR/HER2 heterodimers resulting in a 72% reduction. Cetuximab, Trastuzumab or Pertuzumab (anti-HER2) alone induced a 48, 44, or 24% reduction, respectively. In contrast, the tyrosine kinase inhibitors Erlotinib and Lapatinib had very little effect on EGFR/HER2 dimers concentration. In vivo, the combination of Cetuximab and Trastuzumab showed a better therapeutic effect (median survival and percentage of tumor-free mice) than the single mAbs. These results suggest a correlation between the extent of the mAb-induced EGFR/HER2 heterodimer reduction and the efficacy of such mAbs in targeted therapies. In conclusion, quantifying EGFR/HER2 heterodimers using our antibody-based TR-FRET assay may represent a useful method to predict the efficacy and explain the mechanisms of action of therapeutic mAbs, in addition to other commonly used techniques that focus on antibody-dependent cellular cytotoxicity, phosphorylation, and cell proliferation. © 2011 by The American Society for Biochemistry and Molecular Biology, Inc.

Loading Cisbio collaborators
Loading Cisbio collaborators